CRO/Sponsor

In this video interview, Michel van Harten, MD, CEO, myTomorrows, discusses where the clinical research industry currently stands with AI adoption.

Overcoming hurdles with licensing complexities, post-production changes, and IRB submissions can help in reducing timelines and increasing collaboration.

Companies share their experience in future-proofing clinical data technology.

How today’s SSO reduces site burden and spearheads clinical system interoperability.

In this video interview, Rob Jones, product manager, TMF practice area, Pharmalex, shares his key takeaways from Cencora’s recent TMF Leadership Summit and touches on the importance of oversight when working with outside stakeholders.

Strategies for ensuring that innovation with PROs remains parallel with advancements in disease detection and progression.

With close collaboration between sponsors, CROs, and regulators, this emerging technology has the potential to greatly improve the lives of patients.

In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, talks traditional research methods in clinical trials and why industry leaders remain reliant on them.

Survey from the Site Council gathered insights from its members on the quality of site coordinator work.

Addressing data integrity and compliance concerns.

This year’s conference highlighted a number of critical areas in clinical R&D including financial management, representation, and eCOA.

In this video interview, Dominique Demolle, CEO of Cognivia, discusses challenges that sponsors are currently facing with adherence and some strategies that can help address them.

Examining those technology-supported areas that sponsors, CROs, and sites consider the most valuable.

Insights identify opportunities to optimize sponsor, CRO, and site collaborations.

Clinical trial liaisons rather serve as experts in their therapeutic areas and as clinical trial specialists to provide a suite of strategic advantages to benefit a study.

A focus on data and process excellence advances product development.

In this video interview, Rachael Fones, director, government & public affairs, IQVIA, discusses some of the key ways that different trial sponsors may need support in meeting diversity expectations.

How a deeper review of site budget and payment processes and technology is driving meaningful change in the industry.

Strategies for sponsors to utilize technology in reaching diverse patient populations.

Balancing these tools with operational efficiencies can aid CROs in meeting the evolving needs of sponsors.

Use cases spotlight the growing potential of generative AI in the CRO space.

A well-designed approach can benefit clinical trials from protocol design to site support.

Palmese, executive director, site relationships and DCT solutions, discusses the practice of incorporating decentralized elements in a study rather than planning a decentralized trial from the start.

Sponsors and CROs that work with these sites can better reach marginalized communities.

In this video interview, Kelli Aufderheide, director, laboratory decentralized trial solutions, IQVIA Laboratories, highlights how stakeholders can best support sites throughout complex studies.

In this video interview, Kelli Aufderheide, director, laboratory decentralized trial solutions, IQVIA Laboratories, touches on how therapeutic area can affect which labs a sponsor decides to work with.

Results from survey of 100 site personnel suggest a disconnect is present between these stakeholders.

In this video interview, Kelli Aufderheide, director, laboratory decentralized trial solutions, IQVIA Laboratories, highlights best practices for data standardization and consistency.

In this video interview, Kelli Aufderheide, director, laboratory decentralized trial solutions, IQVIA Laboratories, discusses the different types of labs in clinical research and what they offer.

In this video interview, Jimmy Bechtel, vice president, site engagement, SCRS, discusses the importance of communication between CROs, sponsors, and sites.